A Phase 2/3 interventional study of Atomoxetine and Placebo in Attention Deficit Hyperactivity Disorder, sponsored by Eli Lilly and Company. Completed at 24 sites in Japan. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2007-11-06.
Sponsored by Eli Lilly and Company · Phase 2/3, Interventional, and Treatment
Atomoxetine versus placebo in Children with Attention-Deficit/Hyperactivity Disorder (ADHD)
729 studies on the registry are indexed under Hyperkinesis; 25 are open to participants now.
This study's enrollment of 240 is above the median of 80 across 583 interventional studies indexed under Hyperkinesis.
Browse Hyperkinesis studies →Eli Lilly and Company is the lead sponsor of 2,048 studies on the registry; 140 are open to participants now.
Of its 521 completed or terminated interventional studies of FDA-regulated products, 341 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Change of total score on ADHD RS-IV-JParent Version: Investigation-Administered and Scored
Relationship between atomoxetine doses and both efficacy and safety variables
Plasma concentration of atomoxetine and its metabolites
Changes on ADHD RS-IV-J-School Version score
This study is completed, as verified in Nov 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eli Lilly and Company